Miettinen M, Sarlomo-Rikala M, Kovatich A J
Armed Forces Institute of Pathology, Department of Soft Tissue Pathology, Washington, DC 20306-6000, USA.
Virchows Arch. 1998 Sep;433(3):255-60. doi: 10.1007/s004280050244.
Bcl-2 is one of the many proteins that regulate programmed cell death and is overexpressed in B-cell lymphomas. The expression of bcl-2 in mesenchymal cells and soft tissue tumours was the subject of this study. Normal mesenchymal tissue and representative cases of soft tissue tumours of different types (n>200) were investigated immunohistochemically for bcl-2 expression. Although bcl-2 expression was normally relatively restricted to some smooth muscle cells and neural cells, bcl-2 immunoreactivity was widespread in different types of soft tissue neoplasms, both benign and malignant. Consistently positive tumours included solitary fibrous tumour, haemangiopericytoma, schwannoma and synovial sarcoma. The few soft tissue tumours that were consistently negative for bcl-2 included nodular fasciitis and desmoid tumour. Leiomyomas and leiomyosarcomas were heterogeneous; all uterine leiomyomas were bcl-2 positive, but all oesophageal leiomyomas were negative, paralleling the reactivity observed in the smooth muscle at those sites. Gastrointestinal stromal tumours showed bcl-2 reactivity; this was less consistent in malignant tumours. Along the malignancy gradient, there was no consistent trend in the bcl-2 reactivity. Dermatofibrosarcomas showed increase of bcl-2 expression with fibrosarcomatous transformation, whereas smooth muscle sarcomas and malignant peripheral nerve sheath sarcomas were less consistently positive than the corresponding benign neoplasms. We conclude that bcl-2 expression is widespread in soft tissue tumours, but shows constitutional expression patterns that are often parallel to the normal tissue counterparts. Compared with benign soft tissue tumours, bcl-2 expression is often reduced in sarcomas, but it cannot be used as a prognostic marker without correlation of the data to its phenotypic expression patterns.
Bcl-2是众多调节程序性细胞死亡的蛋白质之一，在B细胞淋巴瘤中过度表达。本研究的主题是Bcl-2在间充质细胞和软组织肿瘤中的表达。采用免疫组织化学方法研究了正常间充质组织和不同类型软组织肿瘤的代表性病例（n>200）中Bcl-2的表达情况。虽然Bcl-2的表达通常相对局限于一些平滑肌细胞和神经细胞，但Bcl-2免疫反应性在不同类型的良性和恶性软组织肿瘤中广泛存在。持续阳性的肿瘤包括孤立性纤维瘤、血管外皮细胞瘤、神经鞘瘤和滑膜肉瘤。少数对Bcl-2持续阴性的软组织肿瘤包括结节性筋膜炎和硬纤维瘤。平滑肌瘤和平滑肌肉瘤具有异质性；所有子宫平滑肌瘤Bcl-2呈阳性，但所有食管平滑肌瘤均为阴性，这与在这些部位平滑肌中观察到的反应性一致。胃肠道间质瘤显示Bcl-2反应性；在恶性肿瘤中这种反应性不太一致。沿着恶性程度梯度，Bcl-2反应性没有一致的趋势。皮肤纤维肉瘤在发生纤维肉瘤样转化时Bcl-2表达增加，而平滑肌肉瘤和恶性外周神经鞘膜肉瘤的阳性程度不如相应的良性肿瘤一致。我们得出结论，Bcl-2表达在软组织肿瘤中广泛存在，但显示出通常与正常组织对应物平行的构成性表达模式。与良性软组织肿瘤相比，Bcl-2表达在肉瘤中常降低，但在未将数据与其表型表达模式相关联的情况下，它不能用作预后标志物。
